Allergy Relief D tablets recalled for failed dissolution specifications
Dr. Reddy's Laboratories is recalling Allergy Relief D extended-release tablets distributed nationwide by Walmart due to failed dissolution specifications. No illnesses or injuries have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class III recall, which means the violation is unlikely to cause adverse health consequences. No illnesses or injuries have been reported. The hazard is a manufacturing quality issue affecting dissolution and potentially medication efficacy, not a direct safety threat.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Allergy Relief D Extended-Release Tablets containing Fexofenadine HCL 60mg (antihistamine) and Pseudoephedrine HCL 120mg (nasal decongestant). The product was distributed nationwide by Walmart Inc. in 20-count and 30-count packages.
The recall is due to failed dissolution specifications, meaning the tablets do not dissolve at the specified rate. This manufacturing defect may affect proper absorption and effectiveness of the medication. The FDA has classified this as a Class III recall.
The affected lot numbers are AC2203133B and AC2203133A, both expiring January 2024. Consumers who have this product should stop using it and contact their pharmacist or healthcare provider for guidance on obtaining a replacement medication.
The recalled product
- Product
- Allergy Relief D, Fexofenadine HCL 60mg/Antihistamine, Pseudoephedrine HCL 120mg/Nasal Decongestant, Extended-Release Tablets USP, packaged as (a) 20 count carton NDC 49032-273-20; (b) 30 count carton, NDC49032-273-30; Distributed by: Walmart Inc., Bentonville, AR 72716, Product
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot# (a) AC2203133B
- EXP 01/2024
- (b) AC2203133A
- EXP 01/2024.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · dissolution failure
See all →- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17